Sam Brusco, Associate Editor01.27.23
Roche and Sysnav Healthcare began a partnership to develop industry-standard measurements for movement impairment-associated diseases, and designed next-gen wearable technology based on Sysnav’s technology.
Sysnav has developed medical-grade wearables based on its magneto-inertial tech for 3D movement reconstruction. This allows for precise tracking of movement without GPS, protecting patient privacy while enabling indoor monitoring. The company achieved the first-ever qualification of a digital endpoint (SV95c) with the European Medicines Agency for Duchenne's Muscular Dystrophy, having collaborated with academic collaborators, patients associations, and Roche.
Sysnav and Roche expanded their partnership across multiple programs to build meaningful digital endpoints to monitor neuromuscular disease progression, support clinical trials, and act as a regulatory approved standards of outcome measurement.
The collaboration also aims to create the next-gen wearable tech to further promote personalized medicine.
"Sysnav's technology offers the opportunity to measure functional disease progression to a regulatory standard across a range of diseases. This has the potential to improve the way patients are involved in clinical studies, the ability to determine potential treatment benefits, and enrich our understanding of disease pathophysiology," James Sabry, Global Head of Roche Pharma Partnering told the press.
"When high precision technology meets clinical expertise, it is a game-changing combination to accelerate medical progress. Bringing together Sysnav's digital health technology and Roche's expertise in neuroscience drug development and personalized healthcare will enable us to have a truly meaningful impact on patients with motor impairments. By establishing a new set of industry standards for the evaluation of motor impairments, we can unlock innovation for the benefit of all patients," added Damien Eggenspieler, Sysnav Healthcare Program Director.
Sysnav has developed medical-grade wearables based on its magneto-inertial tech for 3D movement reconstruction. This allows for precise tracking of movement without GPS, protecting patient privacy while enabling indoor monitoring. The company achieved the first-ever qualification of a digital endpoint (SV95c) with the European Medicines Agency for Duchenne's Muscular Dystrophy, having collaborated with academic collaborators, patients associations, and Roche.
Sysnav and Roche expanded their partnership across multiple programs to build meaningful digital endpoints to monitor neuromuscular disease progression, support clinical trials, and act as a regulatory approved standards of outcome measurement.
The collaboration also aims to create the next-gen wearable tech to further promote personalized medicine.
"Sysnav's technology offers the opportunity to measure functional disease progression to a regulatory standard across a range of diseases. This has the potential to improve the way patients are involved in clinical studies, the ability to determine potential treatment benefits, and enrich our understanding of disease pathophysiology," James Sabry, Global Head of Roche Pharma Partnering told the press.
"When high precision technology meets clinical expertise, it is a game-changing combination to accelerate medical progress. Bringing together Sysnav's digital health technology and Roche's expertise in neuroscience drug development and personalized healthcare will enable us to have a truly meaningful impact on patients with motor impairments. By establishing a new set of industry standards for the evaluation of motor impairments, we can unlock innovation for the benefit of all patients," added Damien Eggenspieler, Sysnav Healthcare Program Director.